Cost Effectiveness of Recombinant Zoster Vaccine and Live-Attenuated Vaccine Against Herpes Zoster for Adults Aged 50 and Over in China.

ABSTRACT:

Objective

Two vaccines against herpes zoster (HZ) are currently authorized for use in China: the adjuvanted recombinant zoster vaccine (RZV) and live-attenuated Zoster Vaccine Live (ZVL). The significant disparities in prices and efficacy between the two vaccines necessitate an evaluation of their relative value in order to make an informed choice. This study aimed to evaluate the comparative cost effectiveness of RZV, ZVL, and no vaccination for older adults at different ages from the societal perspective.

Methods

The Markov decision model was parameterized using vaccine efficacy data, the latest incidence rates, costs, and health-related quality-of-life data. Participants consisted of a cohort comprising adults aged ≥ 50 years in China. The lifetime health impacts, cost, l

SUBMITTER: Liu L 

PROVIDER: S-EPMC12559535 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature